CN102482334A - Sparc血管发生结构域及使用方法 - Google Patents

Sparc血管发生结构域及使用方法 Download PDF

Info

Publication number
CN102482334A
CN102482334A CN201080018313XA CN201080018313A CN102482334A CN 102482334 A CN102482334 A CN 102482334A CN 201080018313X A CN201080018313X A CN 201080018313XA CN 201080018313 A CN201080018313 A CN 201080018313A CN 102482334 A CN102482334 A CN 102482334A
Authority
CN
China
Prior art keywords
tumors
polypeptide
seq
sparc
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080018313XA
Other languages
English (en)
Chinese (zh)
Inventor
V·德留
D·瑙尔
N·德赛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Publication of CN102482334A publication Critical patent/CN102482334A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201080018313XA 2009-03-11 2010-03-11 Sparc血管发生结构域及使用方法 Pending CN102482334A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15932209P 2009-03-11 2009-03-11
US61/159,322 2009-03-11
PCT/US2010/027041 WO2010105097A2 (en) 2009-03-11 2010-03-11 Sparc angiogenic domain and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410016511.2A Division CN103724417A (zh) 2009-03-11 2010-03-11 Sparc血管发生结构域及使用方法

Publications (1)

Publication Number Publication Date
CN102482334A true CN102482334A (zh) 2012-05-30

Family

ID=42729116

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080018313XA Pending CN102482334A (zh) 2009-03-11 2010-03-11 Sparc血管发生结构域及使用方法
CN201410016511.2A Pending CN103724417A (zh) 2009-03-11 2010-03-11 Sparc血管发生结构域及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410016511.2A Pending CN103724417A (zh) 2009-03-11 2010-03-11 Sparc血管发生结构域及使用方法

Country Status (13)

Country Link
US (2) US20120087910A1 (enExample)
EP (1) EP2405932A4 (enExample)
JP (1) JP2012520081A (enExample)
KR (2) KR20130043242A (enExample)
CN (2) CN102482334A (enExample)
AU (1) AU2010224031B2 (enExample)
BR (1) BRPI1009457A2 (enExample)
CA (1) CA2755109A1 (enExample)
IL (2) IL215089A0 (enExample)
MX (1) MX2011009478A (enExample)
NZ (1) NZ595528A (enExample)
WO (1) WO2010105097A2 (enExample)
ZA (1) ZA201107415B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120361186A (zh) * 2025-04-15 2025-07-25 北京大学口腔医学院 一种促进血管生成和组织再生的药物组合物及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011112921A2 (en) * 2010-03-11 2011-09-15 Abraxis Bioscience, Llc Sparc angiogenic domain and methods of use
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255035A1 (en) * 2007-04-13 2008-10-16 Abraxis Bioscience, Inc. Sparc and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000677A1 (en) * 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2006112930A2 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
ES2406929T3 (es) * 2006-06-26 2013-06-10 The University Of British Columbia Proteína secretada ácida y rica en cisteína (SPARC) como sensibilizantes quimioterapéuticos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255035A1 (en) * 2007-04-13 2008-10-16 Abraxis Bioscience, Inc. Sparc and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELLEN JENDRASCHAK ET AL.: "Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology", 《SEMIMARS IN CANCER BIOLOGY》 *
TF LANE，ET AL: "The biology of SPARC, a protein that modulates cell-matrix interactions", 《THE FASEB JOURNAL》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120361186A (zh) * 2025-04-15 2025-07-25 北京大学口腔医学院 一种促进血管生成和组织再生的药物组合物及其应用

Also Published As

Publication number Publication date
WO2010105097A2 (en) 2010-09-16
AU2010224031A1 (en) 2011-10-06
ZA201107415B (en) 2012-06-27
US20120087910A1 (en) 2012-04-12
IL228795A0 (en) 2013-12-31
KR20130043242A (ko) 2013-04-29
AU2010224031A2 (en) 2011-10-20
IL215089A0 (en) 2011-11-30
US20140094416A1 (en) 2014-04-03
KR20110139256A (ko) 2011-12-28
EP2405932A4 (en) 2012-08-22
NZ595528A (en) 2013-10-25
JP2012520081A (ja) 2012-09-06
CN103724417A (zh) 2014-04-16
MX2011009478A (es) 2011-11-18
WO2010105097A3 (en) 2010-11-04
AU2010224031B2 (en) 2013-05-02
EP2405932A2 (en) 2012-01-18
WO2010105097A8 (en) 2011-05-26
BRPI1009457A2 (pt) 2016-03-01
CA2755109A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
EA011583B1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
JP6884134B2 (ja) 良性前立腺過形成の患者における手術の必要性を低減する方法
JP6941605B2 (ja) 望まれない細胞増殖の除去又は破壊を必要とする疾患を治療するための組み合わせ組成物
EA019476B1 (ru) АНТИТЕЛА ПРОТИВ IL-23p19 И ИХ ПРИМЕНЕНИЕ
CN103169959A (zh) 用于治疗呈现存活蛋白抗原的肿瘤的组合物和方法
CN102482334A (zh) Sparc血管发生结构域及使用方法
TWI748957B (zh) 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物
JP2023011938A (ja) ファーバー病を治療するための組成物及び方法
JP2002502369A (ja) 胃腸管上部の機能を強化する方法
JP2015518835A (ja) 癌幹細胞を標的とした癌ワクチン
US20210106652A1 (en) Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
US20210403586A1 (en) Mutant of rankl and pharmaceutical composition comprising same for preventing or treating osteoporosis
TWI649332B (zh) Composition for promoting local muscle growth, slowing or preventing local muscle atrophy and use thereof
JP2018514583A (ja) 疼痛治療
TW201408321A (zh) 治療癌症之協同組合
JP2019526539A (ja) 急性尿閉の発生を予防または低減させる方法
KR20130010477A (ko) Ｓｐａｒｃ 혈관형성 영역과 사용방법
EP3277312A2 (en) Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumoral immunity
JP2015067579A (ja) 細胞透過性ペプチド及び当該ペプチドを含む医薬組成物。
CN113966227A (zh) 疫苗佐剂以及制剂
WO2019045025A1 (ja) ワクチン組成物
JP2011093806A (ja) 膠原病の予防・治療剤
HK1194403A (en) Sparc angiogenic domain and methods of use
Khansari Contribution of interleukin-11 and prostaglandin (s) in lipopolysaccharide-induced bone resorption in vivo
EA044461B1 (ru) Способ лечения опухолей

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1167664

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120530

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1167664

Country of ref document: HK